Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogenn activator in acute myocardial infarction

Article Abstract:

A coronary stent plus the drug abciximab appears to be more effective for heart attack patients than tissue plasminogen activator (tPA), according to a study of 140 patients. A stent is a small cylinder that keeps an artery open, abciximab is an anticoagulant, and tPA breaks up the blood clots that cause most heart attacks.

Author: Schomig, Albert, Kastrati, Adnan, Dirschinger, Josef, Mehilli, Julinda, Schricke, Ullrich, Pache, Jurgen, Martinoff, Stefan, Neumann, Franz-Josef, Schwaiger, Markus
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Care and treatment

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

Article Abstract:

The anticoagulant drug abciximab appears to improve blood flow and decrease postoperative mortality rates in heart attack patients who receive a stent. Stents are small cylindrical devices that are inserted in arteries to keep them open.

Author: Montalescot, Gilles, Barragan, Paul, Wittenberg, Olivier, Ecollan, Patrick, Elhadad, Simon, Villain, Philippe, Boulenc, Jean-Marc, Morice, Marie-Claude, Maillard, Luc, Pansieri, Michel, Choussat, Remi, Pinton, Philippe
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

Article Abstract:

A study is conducted enrolling 3491 patients in the age group of 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel or placebo. In patients 75 years or younger who have myocardial infraction with ST-segment elevation, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications.

Author: Gibson, C. Michael, McCabe, Carolyn H., Braunwald, Eugene, Montalescot, Gilles, Sabatine, Marc S., Theroux, Pierre, Skene, Allan M., Hill, Karen A., Claeys, Marc J., Cools, Frank, Lopez-Sendon, Jose L.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United Kingdom, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Blood Clot Dissolvers, Usage, Plavix (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Heart attack, Anticoagulants (Medicine), Anticoagulants, Fibrinolytic agents, Stent (Surgery), Thrombolytic drugs, Stents, Drug therapy
Similar abstracts:
  • Abstracts: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
  • Abstracts: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.